Ellen Van Gulck

Beerse, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Correction for Raines et al., "Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets".

Correction for Raines et al., "Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets".

Journal: Antimicrobial agents and chemotherapy
Published: July 21, 2025

Blood and tissue HIV-1 reservoirs display plasticity and lack of compartmentalization in virally suppressed people.

Blood and tissue HIV-1 reservoirs display plasticity and lack of compartmentalization in virally suppressed people.

Journal: Nature communications
Published: August 28, 2024

Correction for Van Gulck et al., "A truncated HIV Tat demonstrates potent and specific latency reversal activity".

Correction for Van Gulck et al., "A truncated HIV Tat demonstrates potent and specific latency reversal activity".

Journal: Antimicrobial agents and chemotherapy
Published: July 02, 2024

Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets.

Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets.

Journal: Antimicrobial agents and chemotherapy
Published: June 03, 2024

AAV-HBV mouse model replicates the intrahepatic immune landscape of chronic HBV patients at single-cell level.

AAV-HBV mouse model replicates the intrahepatic immune landscape of chronic HBV patients at single-cell level.

Journal: Frontiers in immunology
Published: April 22, 2024

Robust isolation protocol for mouse leukocytes from blood and liver resident cells for immunology research.

Robust isolation protocol for mouse leukocytes from blood and liver resident cells for immunology research.

Journal: PloS one
Published: February 09, 2024

Retreatment with HBV siRNA Results in Additional Reduction in HBV Antigenemia and Immune Stimulation in the AAV-HBV Mouse Model.

Retreatment with HBV siRNA Results in Additional Reduction in HBV Antigenemia and Immune Stimulation in the AAV-HBV Mouse Model.

Journal: Viruses
Published: February 05, 2024

mRNA Therapeutic Vaccine for Hepatitis B Demonstrates Immunogenicity and Efficacy in the AAV-HBV Mouse Model.

mRNA Therapeutic Vaccine for Hepatitis B Demonstrates Immunogenicity and Efficacy in the AAV-HBV Mouse Model.

Journal: Vaccines
Published: January 19, 2024

Sustained Liver HBsAg Loss and Clonal T- and B-Cell Expansion upon Therapeutic DNA Vaccination Require Low HBsAg Levels.

Sustained Liver HBsAg Loss and Clonal T- and B-Cell Expansion upon Therapeutic DNA Vaccination Require Low HBsAg Levels.

Journal: Vaccines
Published: October 29, 2023

A truncated HIV Tat demonstrates potent and specific latency reversal activity.

A truncated HIV Tat demonstrates potent and specific latency reversal activity.

Journal: Antimicrobial agents and chemotherapy
Published: October 24, 2023

Potent latency reversal by Tat RNA-containing nanoparticle enables multi-omic analysis of the HIV-1 reservoir.

Potent latency reversal by Tat RNA-containing nanoparticle enables multi-omic analysis of the HIV-1 reservoir.

Journal: Nature communications
Published: May 10, 2023

A Therapeutic Hepatitis B Virus DNA Vaccine Induces Specific Immune Responses in Mice and Non-Human Primates.

A Therapeutic Hepatitis B Virus DNA Vaccine Induces Specific Immune Responses in Mice and Non-Human Primates.

Journal: Vaccines
Published: May 26, 2021
Showing 1-12 of 23

Last Updated: 09/26/2026